Dublin, Oct. 12, 2021 (GLOBE NEWSWIRE) -- The "Companion Diagnostic Markets 2021-2025" report has been added to ResearchAndMarkets.com's offering.
This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail.
Forecast demand for new testing regimes or technologies. Make research investment decisions. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth.
Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for this important market.
Learn all about how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities.
And some players are already taking the lead. It is a dynamic market situation with enormous opportunity. Diagnostic companies are trying to back the right horse. The science is racing forward. And the cost of molecular diagnostics continues to fall.
Factors Driving Growth
Level of Care
Factors Limiting Growth
State of knowledge
Regulation and coverage
Instrumentation and Automation
Instruments Key to Market Share
Bioinformatics Plays a Role
Diagnostic Technology Development
Next Generation Sequencing Fuels a Revolution
Single Cell Genomics Changes the Picture
Pharmacogenomics Blurs Diagnosis and Treatment
CGES Testing, A Brave New World
Biochips/Giant magneto resistance based assay
Companion Diagnostics Recent Developments
HTG Molecular Diagnostics 2020 Revenues Fall 56%
Oncocyte Details Expansions Plans
Agilent Acquires Resolution Biosciences
Qiagen, Inovio Expand CDx Partnership
AmoyDx, AstraZeneca Strike Ovarian Cancer CDx Alliance
NeoGenomics to Grow Through CDx Agreements, Acquisitions
Personalis Neoantigen Platform Driving Improved Immunotherapy Prediction
Biocartis Collaborating with Endpoint Health on CDx Tests for Idylla Platform
FDA Approves Foundation Medicine Test as CDx for Three Targeted Therapies
Promega to Develop MSI Assay as CDx
HTG Molecular Q2 Revenues Drop 66 Percent
Guardant Health to Develop CDx for Janssen
Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx .
FDA Approval for FoundationOneCDx
FDA finalizes CDx Guidance
QIAGEN Launches CDx Therascreen BRAF Test
Myriad Genetics Seeks Approval for Companion Diagnostic
ARUP Labs Seek PMA for Hemophilia Gene Therapy CDx
QIAGEN Builds on Global Collaboration with Amgen
Foundation Medicine nabs 19th companion Dx
Maze Therapeutics Uses CRISPR for Precision Medicine Companion Diagnostics
Myriad Wins Japanese Approval for BRACAnalysis
Fujitsu Improves Efficiency in Cancer Genomic Medicine
Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results
Takeda, Prometheus Enter IBD Drug-Companion Diagnostic Partnership
Thermo Fisher, Eli Lilly Ink CDx Collaboration in NSCLC, Thyroid Cancer
Roche VENTANA PD-L1 (SP142) Assay approved as companion diagnostic
Universal Genetic Testing for All Breast Cancer Patients
Exact Sciences buys Genomic Health
Biodesix Highlights Pipeline and Companion Diagnostic Development
10x Genomics, Inc
Agena Bioscience, Inc.
Baylor Miraca Genetics Laboratories
Beckman Coulter Diagnostics
Becton, Dickinson and Company
BGI Genomics Co. Ltd
Bio-Rad Laboratories, Inc
Caris Molecular Diagnostics
Castle Biosciences, Inc.
Cepheid (now Danaher)
Charles River Laboratories
Cytolumina Technologies Corp
Datar Cancer Genetics Limited
Enzo Life Sciences, Inc
Genetron Health (Beijing) Co., Ltd.
HTG Molecular Diagnostics
MDNA Life SCIENCES, Inc
Menarini Silicon Biosystems
Myriad Genetics/Myriad RBM
Novogene Bioinformatics Technology Co., Ltd.
Ortho Clinical Diagnostics
Oxford Nanopore Technologies
Personal Genome Diagnostics
Roche Molecular Diagnostics
Singlera Genomics Inc
Tempus Labs, Inc
Thermo Fisher Scientific Inc
Thrive Earlier Detection
For more information about this report visit https://www.researchandmarkets.com/r/vord04
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900